Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Proximagen Acquires CNS Research Programs From GlaxoSmithKline

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

GlaxoSmithKline retains the value of two CNS research programs in the U.K. by divesting them to Proximagen

You may also be interested in...



Upsher-Smith To Buy U.K. Biotech Partner Proximagen For $347 Million

Proposed acquisition mimics other recent M&A deals, like Sanofi/Genzyme, with inclusion of contingent-value rights pegged to success of two clinical candidates.

Lundbeck Invests £10M In CNS-Focused Proximagen

Lundbeck's support for Proximagen comes as biotechs struggle for survival in the high-risk CNS space.

Lundbeck Invests £10M In CNS-Focused Proximagen

Lundbeck's support for Proximagen comes as biotechs struggle for survival in the high-risk CNS space.

Table

View full table

Related Content

Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

COVID-19 Vaccine Strain Updates Don’t Exactly Fit Flu Model

Medicare Price Negotiation: Special Treatment For ‘Novel Technologies’ On PhRMA’s Advocacy Agenda

As Quantity Of Cannabis IND Applications Grows, US FDA Has ‘Quality Considerations’ Guidance

ABPI President Steps Down Amid Novo Nordisk Code Of Practice Breach

See All
UsernamePublicRestriction

Register

PS071644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By